U.S. markets open in 3 hours 27 minutes
  • S&P Futures

    4,291.00
    -7.25 (-0.17%)
     
  • Dow Futures

    33,854.00
    -19.00 (-0.06%)
     
  • Nasdaq Futures

    13,653.25
    -28.00 (-0.20%)
     
  • Russell 2000 Futures

    2,021.00
    -2.80 (-0.14%)
     
  • Crude Oil

    88.97
    -0.44 (-0.49%)
     
  • Gold

    1,790.80
    -7.30 (-0.41%)
     
  • Silver

    20.05
    -0.23 (-1.12%)
     
  • EUR/USD

    1.0138
    -0.0027 (-0.26%)
     
  • 10-Yr Bond

    2.7910
    0.0000 (0.00%)
     
  • Vix

    20.04
    +0.51 (+2.61%)
     
  • GBP/USD

    1.2024
    -0.0034 (-0.28%)
     
  • USD/JPY

    134.0400
    +0.7680 (+0.58%)
     
  • BTC-USD

    24,094.10
    -83.79 (-0.35%)
     
  • CMC Crypto 200

    572.90
    -17.86 (-3.02%)
     
  • FTSE 100

    7,551.80
    +42.65 (+0.57%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host a full year 2020 investor conference call and webcast on Monday, March 29, 2021 at 9:00 a.m. EDT. The F-star Therapeutics management team, including Eliot Forster, CEO and Darlene Deptula-Hicks, CFO, will discuss 2020 financial results and provide a corporate update.

To access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations or participants can dial 1-833-471-0868 in the US/Canada or 1-914-987-7751 for International calls, at least 10 minutes prior to the start of the call.

A replay of the conference call will be available beginning March 30, 2021 and may be accessed in the Investors & News/Events and Presentations section on the F-star Therapeutics website for 90 days.

About F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit https://www.f-star.com/ and follow us on LinkedIn and Twitter.

For further information, please contact:

For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com

For media inquiries
Helen Shik
Shik Communications LLC
617-510-4373
Shik.Helen10@gmail.com